The shrooms-to-pharma pipeline just got a VIP pass
On Saturday, the president was in the Oval Office with Joe Rogan, Robert F. Kennedy Jr., FDA Commissioner Marty Makary, and a line of veterans when he signed an executive order to fast-track psychedelic drugs through the FDA. That is not your average policy photo op. That’s Washington basically saying, “Fine, let’s put the weird stuff on the conveyor belt and see what happens.”
Why investors care
The FDA said it will issue three national priority vouchers next week for what Makary called “serotonin 2A agonists” — which is science-speak for the class of compounds that includes a lot of the psychedelic pipeline. Makary also said the first ibogaine investigational new drug clearance has already been issued, and that some approvals could happen in weeks if the program moves as advertised.
The fine print matters
This isn’t a free-for-all. The administration said treatments would require a controlled setting, with two people in the room and conditions more like an ICU or operating room than a chill playlist and a beanbag. So yes, the market is getting a potential regulatory tailwind — but this is still medicine, not a festival.
Big picture
If you own names tied to psychedelic therapeutics, this is the kind of policy shift that can turn “someday” into “maybe sooner than you thought.” The market will now start pricing not just science, but the speed of the FDA lane — and that’s often where the real volatility lives.